InsiderSignal.AI

InsiderSignal.ai

UTHR - United Therapeutics Corp

Insider Sale by Rothblatt Martine A (CHAIRPERSON, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Rothblatt Martine A, serving as CHAIRPERSON, CEO at United Therapeutics Corp (UTHR), sold 9,500 shares at $585.76 per share, for a total transaction value of $5,564,709.00. Following this transaction, Rothblatt Martine A now holds 679,872 shares of UTHR.

This sale represents a 1.00% decrease in Rothblatt Martine A's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 31, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 2, 2026, 2 days after the trade was made.

United Therapeutics Corp operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Rothblatt Martine A

CHAIRPERSON, CEO

Martine A. Rothblatt, Ph.D., MBA, J.D., is the founder, Chairperson, and CEO of United Therapeutics Corporation (UTHR), a biotechnology company she established in 1996 to address unmet medical needs in chronic and life-threatening conditions, particularly pulmonary arterial hypertension (PAH).[[1]](https://www.macmillanspeakers.com/speaker/martine-rothblatt/)[[2]](https://achievement.org/achiever/martine-rothblatt-ph-d/)[[3]](https://en.wikipedia.org/wiki/Martine_Rothblatt) Motivated by her daughter's 1994 diagnosis with life-threatening PAH, Rothblatt pivoted from telecommunications—where she had founded Sirius Satellite Radio (now SiriusXM), served as CEO of Geostar Corporation, and pioneered satellite technologies like PanAmSat and WorldSpace—to medical biotechnology.[[2]](https://achievement.org/achiever/martine-rothblatt-ph-d/)[[3]](https://en.wikipedia.org/wiki/Martine_Rothblatt)[[4]](https://emergeamericas.com/conference-expo/speakers/martine-rothblatt-phd-mba-j-d/) She earned a Ph.D. in medical ethics from Barts and The London School of Medicine and Dentistry in 2001, with a dissertation on xenotransplantation ethics, alongside prior J.D. and M.B.A. degrees from UCLA in 1981.[[1]](https://www.macmillanspeakers.com/speaker/martine-rothblatt/)[[3]](https://en.wikipedia.org/wiki/Martine_Rothblatt) Under Rothblatt's leadership, United Therapeutics developed successful PAH treatments like Orenitram, expanded into neuroblastoma therapies, and innovated in organ transplantation and delivery, including the first drone delivery of donor lungs in 2021 and advancements in eVTOL aircraft for medical transport.[[2]](https://achievement.org/achiever/martine-rothblatt-ph-d/)[[3]](https://en.wikipedia.org/wiki/Martine_Rothblatt) Recognized as the highest-paid female CEO in America in 2013 and top earner in biopharma in 2018, she was named by *Forbes* in 2017 as one of the '100 Greatest Living Business Minds,' highlighting her as a 'perpetual reinventor.'[[1]](https://www.macmillanspeakers.com/speaker/martine-rothblatt/)[[2]](https://achievement.org/achiever/martine-rothblatt-ph-d/)[[3]](https://en.wikipedia.org/wiki/Martine_Rothblatt) Rothblatt also authored books on topics like technological immortality and piloted the first electric helicopter flight between airports in 2022.[[3]](https://en.wikipedia.org/wiki/Martine_Rothblatt)

View full insider profile →

Trade Price

$585.76

Quantity

9,500

Total Value

$5,564,709.00

Shares Owned

679,872

Trade Date

Tuesday, March 31, 2026

5 days ago

SEC Filing Date

Thursday, April 2, 2026

Filed 2 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About United Therapeutics Corp

Company Overview

No company information available
View news mentioning UTHR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5311353

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime